Aripiprazole IM depot as an option for the treatment of bipolar disorder

References

• Kamaradova D, Latalova K, Prasko J, et al. Connection between self-stigma, adherence to treatment, and discontinuation of medication. Patient Prefer Adherence. 2016;10:1289–1298.
   PubMed Web of Science ®Google Scholar
• Berna F, Göritz AS, Llorca PM, et al. Would I take antipsychotics, if I had psychotic symptoms? Examining determinants of the decision to take antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jul 3;77:155–163.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Epub 2017 Sep 29 J Med Econ. 2018;212:127–134.
   PubMed Web of Science ®Google Scholar
• Patel MX, De Zoysa N, Bernadt M, et al. Are depot antipsychotics more coercive than tablets? The patient’s perspective. Epub 2009 Mar 20 J Psychopharmacol. 2010;2410:1483–1489.
   PubMed Web of Science ®Google Scholar
• Kline NS, Simpson GM. A long-acting phenothiazine in office practice. Am J Psychiatry. 1964;120(4):1012–1014.
   PubMedGoogle Scholar
• Wintrob RM. Use of a long-acting phenothiazine in acute manic states. Dis Nerv Syst. 1967;28(5):323–324.
   PubMedGoogle Scholar
• Lagodka A, Ginestet D. Histoire des neuroleptiques d’action prolongée [History of prolonged-action neuroleptics–French]. Encéphale. 2008;34(Suppl.6):S226–S231.
   PubMedGoogle Scholar
• Crocq MA. Histoire des traitements antipsychotiques à action prolongée dans la schizophrénie [A history of antipsychotic long-acting injections in the treatment of schizophrenia–French]. Epub 2015 Jan 15 Encéphale. 2015;411:84–92.
   PubMed Web of Science ®Google Scholar
• Amano T, Matsubayashi H, Momiyama T, et al. Antagonizing effects of a novel antipsychotic quinolinone derivative (OPC-14597) on dopaminergic inhibition of neuronal activities in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(1):105–116.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995;274(1):329–336.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Approval package for 21-436/S-005 & S-008 & 21-713/S-003. Rockville (Maryland): U.S. Food and Drug Administration; 2005.
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP): withdrawal Assessment Report for Abilify International Nonproprietary Name: aripiprazole. Procedure No. EMEA/H/C/0471/II/0063. London. 20. January. 2010. EMA/CHMP/820673/2009. https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-abilify_en.pdf Accessed 2021 Jan 19
   Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Epub 2013 Jul 23 Schizophr Res. 2013;150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617–624.
   PubMed Web of Science ®Google Scholar
• Rohde M, Rk N M, Ae H, et al. Biological conversion of aripiprazole lauroxil – an N-acyloxymethyl aripiprazole prodrug. Results Pharma Sci. 2014;4:19–25.
   PubMedGoogle Scholar
• Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Epub 2015 Dec 19 Expert Rev Clin Pharmacol. 2016;92:169–186.
   PubMed Web of Science ®Google Scholar
• Lundbeck and Otsuka. Abilify Maintena® (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder [news release]. Valby, Denmark, and Tokyo, Japan: Lundbeck; 2017 July 28 [Accessed on 2021 Jan 21]. https://investor.lundbeck.com/static-files/ac2c4cef-3327-4f57-9fb9-f07f575af046
   Google Scholar
• Ehret MJ, Davis E, Luttrell SE, et al. Aripiprazole Lauroxil NanoCrystal® dispersion technology (Aristada Initio®). Clin Schizophr Relat Psychoses. 2018;12(2):92–96.
   PubMedGoogle Scholar
• Hard ML, Wehr AY, Sadler BM, et al. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil. Eur J Drug Metab Pharmacokinet. 2018;43(4):461–469.
   PubMed Web of Science ®Google Scholar
• Rapinesi C, Kotzalidis GD, Mazzarini L, et al. Long-acting injectable (LAI) aripiprazole formulations in the treatment of schizophrenia and bipolar disorder: a systematic review. Clin Drug Investig. 2019;39(8):713–735.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Epub 2009 Jul 21 PLoS Med. 2009;67:e1000097.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry. 2017;78(3):324–331.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. J Affect Disord. 2018;227:649–656. Epub 2017 Oct 24.
   PubMed Web of Science ®Google Scholar
• Cuomo I, Kotzalidis GD, De Persis S, et al. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 2018;14:1645–1656.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a double-blind, placebo-controlled, randomized withdrawal study. J Affect Disord. 2018;241:425–432. Epub 2018 Jul 6.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Jin N, Johnson B, et al. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. Int J Bipolar Disord. 2018;6(1):14.
   PubMed Web of Science ®Google Scholar
• Sh K, Rw L, Rotzinger S, et al., CAN-BIND Investigator Team. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: a CAN-BIND-1 report. J Clin Psychiatry. 2019;80(2):18m12202.
   PubMed Web of Science ®Google Scholar
• Han C, Wang SM, Bahk WM, et al. The potential utility of aripiprazole augmentation for major depressive disorder with mixed features specifier: a retrospective study. Clin Psychopharmacol Neurosci. 2019;17(4):495–502.
   PubMed Web of Science ®Google Scholar
• Albert U, De Cori D, Bogetto F, et al. Hypomania associated with adjunctive low-dose aripiprazole: two case reports and a brief review of the literature. Psychiatr Danub. 2014;26(1):80–83.
   PubMed Web of Science ®Google Scholar
• Hsieh HT, Yeh YW. Aripiprazole augmentation of low-dose sertraline therapy induce hypomania in a liver transplantation recipient: a case report. Am J Ther. 2020;Publish Ahead of Print. Epub ahead of print Sep 7 2020. doi: https://doi.org/10.1097/MJT.0000000000001264
   Google Scholar
• Di Lorenzo R, Ferri P, Cameli M, et al. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183–198.
   PubMed Web of Science ®Google Scholar
• Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007;16(6):771–775.
   PubMed Web of Science ®Google Scholar
• Novi F, Millan MJ, Corsini GU, et al. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D2L receptors are modified by co-transfection of D3 receptors: potential role of heterodimer formation. Epub 2007 May 26 J Neurochem. 2007;1024:1410–1424.
   PubMed Web of Science ®Google Scholar
• Tadori Y, Forbes RA, McQuade RD, et al. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Epub 2008 Sep 20 Eur J Pharmacol. 2008;5971–3:27–33.
   PubMed Web of Science ®Google Scholar
• Takahata K, Ito H, Takano H, et al. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [11C]raclopride and [11C]FLB457. Epub 2012 Jan 12 Psychopharmacology (Berl). 2012;2221:165–172.
   PubMed Web of Science ®Google Scholar
• Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004;493(1–3):75–83.
   PubMed Web of Science ®Google Scholar
• Kegeles LS, Slifstein M, Frankle WG, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology. 2008;33(13):3111–3125. Epub 2008 Apr 16.
   PubMed Web of Science ®Google Scholar
• Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004;10(4):317–336.
   PubMedGoogle Scholar
• Belmaker RH, Agam G. Bipolar disorder: neurochemistry and drug mechanisms. Discov Med. 2005;5(26):191–198.
   PubMedGoogle Scholar
• Bastos JR, Perico KM, Él MV, et al. Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: locomotor response, neuroimmunological profile and pharmacological modulation J Psychiatr Res 2018 102(142–149). Epub 2018 Apr 6. doi: https://doi.org/10.1016/j.jpsychires.2018.04.004.
   Google Scholar
• Yoo S, Kim MY, Cho JY. Syk and Src-targeted anti-inflammatory activity of aripiprazole, an atypical antipsychotic. Biochem Pharmacol. 2018;148:1–12. Epub 2017 Dec 12.
   PubMed Web of Science ®Google Scholar
• Kim MS, Yoo BC, Yang WS, et al. Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action. Oncotarget. 2017;9(5):5979–5992.
   PubMedGoogle Scholar
• Jossin Y. Reelin functions, mechanisms of action and signaling pathways during brain development and maturation. Biomolecules. 2020;10(6):964.
   Web of Science ®Google Scholar
• Roybal DJ, Singh MK, Cosgrove VE, et al. Biological evidence for a neurodevelopmental model of pediatric bipolar disorder. Isr J Psychiatry Relat Sci. 2012;49(1):28–43.
   PubMed Web of Science ®Google Scholar
• Muñoz-Estrada J, Benítez-King G, Berlanga C, et al. Altered subcellular distribution of the 75-kDa DISC1 isoform, cAMP accumulation, and decreased neuronal migration in schizophrenia and bipolar disorder: implications for neurodevelopment. Epub 2015 Jan 24 CNS Neurosci Ther. 2015;215:446–453.
   PubMed Web of Science ®Google Scholar
• Madison JM, Zhou F, Nigam A, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Epub 2015 Mar 3 Mol Psychiatry. 2015;20(6):703–717.
   PubMed Web of Science ®Google Scholar
• Kloiber S, Rosenblat JD, Husain MI, et al. Neurodevelopmental pathways in bipolar disorder. Neurosci Biobehav Rev. 2020;112:213–226. Epub 2020 Feb 5.
   PubMed Web of Science ®Google Scholar
• Levin JB, Krivenko A, Howland M, et al. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs. 2016;30(9):819–835.
   PubMed Web of Science ®Google Scholar
• Greene M, Paladini L, Lemmer T, et al. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. Neuropsychiatr Dis Treat. 2018;14:1545–1559.
   PubMed Web of Science ®Google Scholar
• Tohen M, Goldberg JF, Hassoun Y, et al. Identifying profiles of patients with bipolar I disorder who would benefit from maintenance therapy with a long-acting injectable antipsychotic. J Clin Psychiatry. 2020;81(4):OT19046AH1.
   PubMed Web of Science ®Google Scholar
• García-Carmona JA, Simal-Aguado J, Campos-Navarro MP, et al. Long-acting injectable antipsychotics: analysis of prescription patterns and patient characteristics in mental health from a Spanish real-world study. Clin Drug Investig. 2020;40(5):459–468.
   PubMed Web of Science ®Google Scholar
• Aguilar M, Malcolm B. Effect of long-acting aripiprazole monohydrate on inpatient encounters: a retrospective mirror image study. Ment Health Clin. 2019;9(4):258–262.
   PubMedGoogle Scholar
• Salvi V, Cerveri G, Aguglia A, et al. Off-label use of second-generation antipsychotics in bipolar disorder: a survey of Italian psychiatrists. J Psychiatr Pract. 2019;25(4):318–327.
   PubMed Web of Science ®Google Scholar
• Wong MM-C, Tam K-L, Cheung EY-W, et al. Consensus statements on aripiprazole once-monthly injectable for Hong Kong. Asian J Psychiatr. 2020;54:102394. Epub 2020 Aug 31.
   PubMed Web of Science ®Google Scholar
• Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18(5):440–450.
   PubMed Web of Science ®Google Scholar
• Woods SW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;61(Suppl 13):38–41.
   PubMedGoogle Scholar
• Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–352.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008;23(2):95–105.
   PubMed Web of Science ®Google Scholar
• Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry. 2009 Jul;70(7):1017–1023. . Epub 2009 Jun 2.
   PubMed Web of Science ®Google Scholar
• Gibson S, Brand SL, Burt S, et al. Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. BMC Psychiatry. 2013;13(1):153.
   PubMedGoogle Scholar
• Mago R, Borra D, Mahajan R. Role of adverse effects in medication nonadherence in bipolar disorder. Harv Rev Psychiatry. 2014;22(6):363–366.
   PubMed Web of Science ®Google Scholar
• Yoon HW, Lee JS, Park SJ, et al. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin Neuropharmacol. 2016;39(6):288–294.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Byerly MJ, Nasrallah HA, et al. Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. Epub 2013 Feb 21 Schizophr Res. 2013;1461–3:190–195.
   PubMed Web of Science ®Google Scholar
• Parabiaghi A, Tettamanti M, D’Avanzo B, et al. GiSAS study group. Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Epub 2015 Aug 7 Acta Psychiatr Scand. 2016;1331:63–75.
   PubMed Web of Science ®Google Scholar
• Shymko G, Grace T, Jolly N, et al. Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone). Early Interv Psychiatry. 2020. 2020 Jul 26. Epub ahead of print. doi: https://doi.org/10.1111/eip.13013
   Google Scholar
• Saraf G, Behere RV, Venkatasubramanian G, et al. Hyperprolactinemia with aripiprazole: understanding the paradox. Am J Ther. 2014;21(3):e80–e81.
   PubMed Web of Science ®Google Scholar
• Joseph SP. Aripiprazole-induced hyperprolactinemia in a young female with delusional disorder. Indian J Psychol Med. 2016;38(3):260–262.
   PubMedGoogle Scholar
• Majer IM, Gaughran F, Sapin C, et al. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Mark Access Health Policy. 2015;3:3.
   Google Scholar
• Gentile S. Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Horm Mol Biol Clin Investig. 2017;36(2). doi:https://doi.org/10.1515/hmbci-2017-0004
   Google Scholar
• Preda A, Shapiro BB. A safety evaluation of aripiprazole in the treatment of schizophrenia. Epub 2020 Oct 16 Expert Opin Drug Saf. 2020;1912:1529–1538.
   PubMed Web of Science ®Google Scholar
• Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry. 1985;142(4):499–501.
   PubMed Web of Science ®Google Scholar
• Sachdev P. Reported association of akathisia with suicide. J Nerv Ment Dis. 1992;180(5):339.
   PubMedGoogle Scholar
• Hansen L, Kingdom D. Akathisia as a risk factor for suicide. Br J Psychiatry. 2006;188(2):192.
   PubMedGoogle Scholar